表紙
市場調査レポート

メディカルサイエンスリエゾン (MSL) の活動・業績の評価基準

Charting MSL Activity and Performance

発行 FirstWord 商品コード 226467
出版日 ページ情報 英文 58 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
メディカルサイエンスリエゾン (MSL) の活動・業績の評価基準 Charting MSL Activity and Performance
出版日: 2015年06月01日 ページ情報: 英文 58 Pages
概要

メディカルサイエンスリエゾン (MSL) は、今では製薬会社の「顔」といえる存在であり、新薬の上市に際して医師との折衝を司る重要な役割を果たしています。しかし、職務内容の幅が広いため、企業側ではMSLの付加価値創出への貢献を特定・計測するのが難しくなっています。規制の違い・変動の問題は別にしても、米国と欧州とでは、また現在と将来とでは、MSLの活動内容を評価する基準に違いが生じてくるのでしょうか?

当レポートでは、米国および欧州主要5ヶ国の著名なメディカルサイエンスリエゾン (以下MSL) 80名に対するアンケート調査に基づいて、MSLの活動内容・業績に対する企業内部での評価方法について分析し、MSLの主な活動内容や平均的行動 (担当するブランドの件数、医師との接触機会の件数・時間など)、企業内部での評価手段・基準、地域別・企業別の差異、社内の利害関係者との関係性、評価基準の今後の活用の仕方、といった項目について取り上げております。

MSLの活動

  • 担当しているブランドの件数と責任の範囲
  • MSLの各ブランドへの担当割り当てと、新製品に関する医師との議論
  • MSLの製品上市前/上市後の活動
  • 医師との接触の件数と方法
  • 自ら要望した/相手の要望に応じた折衝に費やした時間

MSLの業績評価

  • 社内でのコミュニケーションの頻度と形態
  • MSLを評価するために用いる業績指標
  • 外面的な価値指標に関する情報収集の方法
  • 業績評価の頻度

組織内の関係者に対するMSLの業績評価の価値証明

  • 価値証明におけるMSLの業績指標の使いやすさ
  • 価値証明におけるMSLの業績指標の変更見通し

専門家の分析

付録

  • 選定基準:MSLのプロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 596200296

A unique survey providing key insights and actionable intelligence. Access expert analysis and data analysis slides in MS PowerPoint and the full data tabulations in MS Excel.

Charting MSL Activity and Performance distils the key findings from one of the most comprehensive surveys of specialist Medical Science Liaison (MSL) personnel in the US and EU5 markets. Informed by the responses and experiences of 80 MSLs, this survey identifies critical variations in MSL activity and presents thought-provoking ideas for the improvement of MSL performance and assessment and how it might change in the future.

Medical Science Liaisons are now the most trusted face of pharma and provide a critically important communication channel with physicians in support of new brands. However, their role has diversified and companies are struggling to identify and measure key MSL outcomes that provide value. Against a background of increasing regulatory oversight, what are the main differences to be found in the US and Europe and what are the current and future approaches to performance measurement that are shaping and defining MSL activity?

Order today to gain insights on how to benchmark your MSL programme and apply engagement techniques used elsewhere.

Gain Answers to Critical Questions

  • At what drug development stage is an MSL team established, how many brands do they handle and how does this differ between the US and Europe?
  • How do MSL performance measurement criteria change pre to post launch?
  • “Building new KOL relationships” is a critical post launch activity but what outcomes are sought and how is success measured?
  • To what extent do US and European views differ on MSL activity in CME, KOL education and publication programmes?
  • What performance criteria do MSL experts see as becoming increasingly important over the near term?
  • Has the rise of new stakeholders changed the way MSL performance is measured?
  • What metrics are companies using to demonstrate MSL value to internal stakeholders?

Report Deliverables

Your report purchase gives you access to unique data and analysis that can be employed practically in your plans and briefings as well as hone your internal performance measurement systems:

  • Data Report: Clear, concise and easy to read tables and charts presented as MS PowerPoint slides with expert views on key findings
  • Data Tabulations: All the data provided in MS Excel
  • Survey Questionnaire: delivered as a PDF document

Key Takeaways

  • Understand which MSL activities are seen as being most important in the US and Europe
  • Benchmark your own MSL programme and identify new ways to improve performance
  • Understand differing US/European attitudes in key areas such payer engagement, KOL education, publication programmes and congress attendance, and challenge accepted norms
  • Examine the importance European MSLs place on training internal sales forces over their US colleagues
  • Identify the most widely used measurements for evaluating KOL engagement and feedback
  • Appreciate the current and future regulatory demands that are impacting MSL activity and prompting a rethink of priorities
  • Understand the current balance between quantitative and qualitative metrics used to measure MSL performance, and assess signals that may indicate a change in the type of metrics used in the future

Table of Contents

MSL Activities

  • Number of Brands Supported and Areas of Responsibility
  • Assignment of MSLs to Brands and Discussion of New Products with Physicians
  • MSL Pre-Launch and Post-Launch Activities
  • Numbers and Methods of Interactions With Physicians
  • Time Spent on Proactive vs. Reactive Engagement

MSL Performance Measurements

  • Internal Communication Frequency and Format
  • Performance Measurements Used to Evaluate MSLs
  • Methods to Gather Information on External Value Metrics
  • Frequency of Performance Review

Value Demonstration to Internal Stakeholders of MSL Performance Measurements

  • Usefulness of MSL Performance Measurements in Value Demonstration
  • Expected Changes in MSL Performance Measurements in Value Demonstration

Expert Analysis

Appendix

  • Screeners - MSL profile
Back to Top